学科主题临床医学
Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy
Xu, Y.1; Diao, L.1; Chen, Y.2; Liu, Y.3; Wang, C.1; Ouyang, T.1; Li, J.1; Wang, T.1; Fan, Z.1; Fan, T.1; Lin, B.1; Deng, D.2; Narod, S. A.4; Xie, Y.1
关键词Brca1 Methylation Chemotherapy Triple-negative Breast Cancer
刊名ANNALS OF ONCOLOGY
2013-06-01
DOI10.1093/annonc/mdt011
24期:6页:1498-1505
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]POLY(ADP-RIBOSE) POLYMERASE ; NEOADJUVANT CHEMOTHERAPY ; MUTATION CARRIERS ; SPORADIC BREAST ; OVARIAN-TUMORS ; EXPRESSION ; SURVIVAL ; SUBTYPES ; THERAPY ; WOMEN
英文摘要

Background: BRCA1 function is inactivated through BRCA1 promoter methylation in a substantial number of triple-negative breast cancers. We investigated the impact of BRCA1-methylation status on the efficacy of adjuvant chemotherapy in patients with triple-negative breast cancer or with non-triple-negative breast cancer.

Methods: BRCA1 promoter methylation was assessed in 1 163 unselected breast cancer patients. Methylation was evaluated using a methylation-specific PCR (MSP) assay.

Results: In the subgroup of 167 triple-negative breast cancer patients who received adjuvant chemotherapy, patients with BRCA1-methylated tumors had a superior 10-year disease-free survival (DFS)(78% versus 55%, P = 0.009) and 10-year disease-specific survival (DSS) (85% versus 69%, P = 0.024) than those with BRCA1-unmethylated tumors, and BRCA1 methylation was an independent favorable predictor of DES and DSS in a multivariate analysis in this subgroup [DFS: hazard ratio (HR) = 0.45; 95% confidence interval (Cl) 0.24-0.84; P = 0.019; DSS: HR = 0.43; 95% CI = 0.19-0.95; P = 0.044]. In contrast, in 675 non-triple-negative breast cancer patients who received adjuvant chemotherapy, BRCA1 methylation was an unfavorable predictor of DFS and DSS in univariate analysis (DFS: HR = 1.56; 95% 01 1.16-2.12; P = 0.003; DSS: HR = 1.53; 95% CI = 1.05-2.21; P=0.026).

Conclusions: Triple-negative breast cancer patients with BRCA1-methylated tumors are sensitive to adjuvant chemotherapy and have a favorable survival compared with patients with BRCA1-unmethylated triple-negative tumors.

语种英语
WOS记录号WOS:000320741500013
项目编号30973436 ; 81071629
资助机构Program for Breast Cancer Tissue Bank of Beijing ; National Natural Science Foundation of China
引用统计
被引频次:30[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56859
专题北京大学临床肿瘤学院_乳腺癌预防治疗中心
北京大学第三临床医学院_血液内科
作者单位1.Univ Toronto, Womens Coll Res Inst, Toronto, ON, Canada
2.Peking Univ, Canc Hosp & Inst, Breast Ctr, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
3.Peking Univ, Canc Hosp & Inst, Etiol Lab, Beijing 100142, Peoples R China
4.Peking Univ, Canc Hosp & Inst, Dept Pathol, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Xu, Y.,Diao, L.,Chen, Y.,et al. Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy[J]. ANNALS OF ONCOLOGY,2013,24(6):1498-1505.
APA Xu, Y..,Diao, L..,Chen, Y..,Liu, Y..,Wang, C..,...&Xie, Y..(2013).Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.ANNALS OF ONCOLOGY,24(6),1498-1505.
MLA Xu, Y.,et al."Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy".ANNALS OF ONCOLOGY 24.6(2013):1498-1505.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Xu, Y.]的文章
[Diao, L.]的文章
[Chen, Y.]的文章
百度学术
百度学术中相似的文章
[Xu, Y.]的文章
[Diao, L.]的文章
[Chen, Y.]的文章
必应学术
必应学术中相似的文章
[Xu, Y.]的文章
[Diao, L.]的文章
[Chen, Y.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。